GroundForce Capital Announces Growth Investment in Epicutis

July 28, 2026

We are excit­ed to share our growth invest­ment in Signum Der­malogix, Inc. (“Epi­cutis”), a sci­ence-backed, IP-dri­ven skin­care brand built around patent­ed, biotech­nol­o­gy-derived actives. Found­ed out of more than 20 years of bio­science research affil­i­at­ed with Prince­ton Uni­ver­si­ty through Signum Bio­sciences, Epi­cutis devel­ops clean, min­i­mal­ist for­mu­la­tions built around its “Skin Health” posi­tion­ing and pro­pri­etary, patent-pro­tect­ed actives, includ­ing TSC, DSD and HYVIA^®.

Read the full press release here.